SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its lead antifungal rezafungin will be presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Madrid, Spain, April 21-24, 2018.
“At this year’s ECCMID meeting Cidara and our collaborators will present a significant amount of new data highlighting the full utility of rezafungin in areas of highest unmet need,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Rezafungin’s potent efficacy against Candida auris and azole-resistant Aspergillus, as well as its substantial penetration into the respiratory tract, strengthens the growing body of evidence differentiating it in the treatment and prophylaxis of deadly invasive fungal infections.”
ECCMID convenes leading experts from around the world to present and discuss the latest research findings in infectious diseases, infection control and clinical microbiology. A total of five presentations at the 2018 ECCMID Congress, comprising four oral presentations and one poster, will report data evaluating Cidara’s lead antifungal rezafungin, the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections.
Details of the five ECCMID presentations are as follows:
Oral Presentations
Title: Multicentre determination of CD101 (rezafungin)
susceptibility of Candida species by the EUCAST method
Author:
Arendrup, et. al.
Date and time: Tuesday, April 24,
9:22-9:32 a.m. CET
Location: Hall K, IFEMA – Feria de Madrid
Presentation
number: #O0938
Oral Session: News on Antifungal Therapy
Title: Rezafungin (CD101) demonstrates potent in vitro activity
against Aspergillus, including azole-resistant A. fumigatus
isolates and cryptic species
Author: Wiederhold, et. al.
Date
and time: Tuesday, April 24, 9:34-9:44 a.m. CET
Location:
Hall K, IFEMA – Feria de Madrid
Presentation number: #O0939
Oral
Session: News on Antifungal Therapy
Title: EUCAST susceptibility testing of rezafungin (CD101):
activity against Candida auris
Author: Arendrup, et.
al.
Date and time: Tuesday, April 24, 10:10-10:20 a.m. CET
Location:
Hall K, IFEMA – Feria de Madrid
Poster number: #O0942
Oral
Session: News on Antifungal Therapy
Title: Pharmacodynamic (PD) evaluation of rezafungin against Candida
auris in the persistently neutropenic murine model of disseminated
candidiasis
Author: Lepak (Andes), et. al.
Date and
time: Tuesday, April 24, 10:34-10:44 a.m. CET
Location: Hall
K, IFEMA – Feria de Madrid
Poster number: #O0944
Oral
Session: News on Antifungal Therapy
Poster Presentation
Title: High and sustained lung epithelial lining fluid
(ELF)-to-plasma exposure ratio from a single dose of rezafungin (CD101):
efficacy comparison to posaconazole and micafungin in a mouse pulmonary
aspergillosis infection model
Author: Ong, et. al.
Date
and time: Saturday, April 21, 3:30-4:30 p.m. CET
Location: Paper
Poster Arena, IFEMA – Feria de Madrid
Poster number: #P0173
Poster
Session: Aspergillus in the Laboratory
Copies of these presentations will be available on the Cidara website following the meeting: www.cidara.com
About Invasive Fungal Infections
Invasive fungal infections (IFIs) represent a serious threat to millions of patients worldwide, resulting in more than 1.5 million deaths annually and mortality rates ranging from 15 to 65 percent. These infections are especially relevant for patients whose immune systems have been compromised, such as patients undergoing bone marrow transplantation (BMT) or chemotherapy. Of the most significant IFIs, approximately 90 percent of related deaths are primarily caused by Candida, Aspergillus, and Pneumocystis. Candida auris (also called C. auris) has become a growing public health concern and can cause bloodstream infections and even death, particularly in hospital and nursing home patients with serious medical problems. According to the Centers for Disease Control and Prevention, more than one in three patients with invasive C. auris infection die.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly known as CD101 IV, through clinical trials. Rezafungin has improved pharmacokinetics compared to existing echinocandins and the potential for expanded utility across patient settings. It is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. The company’s Phase 2 STRIVE clinical trial of rezafungin met its primary safety and efficacy objectives, and Cidara plans to initiate Phase 3 pivotal trials in the treatment of candidemia and invasive candidiasis and the prophylaxis of invasive fungal infections in 2018. Cidara also is leveraging its novel Cloudbreak™ platform to develop antibody-drug conjugates for the treatment of multi-drug resistant Gram-negative bacterial infections. Cloudbreak is the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the potential for rezafungin to successfully treat or prevent invasive fungal infections and represent an improvement over current approaches, and Cidara’s ability to successfully develop rezafungin. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-Q most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
